C5 and infection: While targeting complement always carries a risk of infection, MAC inhibition carries a much reduced risk compared with early pathway inhibition because it does not impair pathogen tagging and opsonization.22,23 For anti-C5 therapies already in the clinic, the risk of Neisseria infection is managed using vaccination and prophylactic antibiotics22; C7 inhibition would require a similar approach to prophylaxis.